Hiv-positive

Also known as: HIV test positive / HIV positve / HIV+ / HIV Positive / HTLV III test positive / HIV positive NOS / HIV test positve / Positive test for HIV / HIV seropositive NOS / HIV Seropositivity

DrugDrug NameDrug Description
DB09102DaclatasvirDaclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Daclatasvir was the first drug with demonstrated safety and therapeutic efficacy in treating HCV genotype 3 without the need for co-administration of interferon or [DB00811]. It exerts its antiviral action by preventing RNA replication and virion assembly via binding to NS5A, a nonstructural phosphoprotein encoded by HCV. Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly. Daclatasvir is shown to target both the cis- and trans-acting functions of NS5A and disrupts the function of new HCV replication complexes by modulating the NS5A phosphorylation status [A19640]. The most common critical NS5A amino acid substitutions that led to reduced susceptibility to daclatasvir therapy occured at position Q30 (Q30H/K/R) and M28 in genotype 1a patients and Y93H in genotype 3 patients. According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg [DB08934] for genotype 1a/b patients with or without cirrhosis as second-line therapy. The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. Combination therapies that include daclatasir can be used for challenging-to-treat patients who have HIV-1 coinfection, advanced cirrhosis, or post-liver transplant recurrence of HCV [L863]. The therapy is intended to cure or achieve a sustained virologic response (SVR12), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [A19626]. Daclatasvir was FDA-approved in July 2015 for use with [DB08934] (Sovaldi) with or without [DB00811] to treat HCV genotype 1 and 3 infections. The SVR12 in HCV genotype 1a-infected treatment-naïve subjects without and with cirrhosis undergoing daclatasvir and [DB08934] therapy were 88% and 99%, respectively [FDA Label]. The same dosing regimen in treatment-naïve patients with HCV genotype 3 infection with or without cirrhosis achieved SVR12 rates of 71% and 98%, respectively [FDA Label].
DB00426FamciclovirFamciclovir is a guanine analogue antiviral drug used for the treatment of various herpes virus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis).
DB00693FluoresceinA phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal injuries and corneal trauma. It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)
DB01141MicafunginMicafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
DB00738PentamidineAntiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. [PubChem]
DB00635PrednisoneA synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
DB00811RibavirinProducing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. It is reported that ribavirin might be only effective in early stages of viral hemorrhagic fevers including Lasser fever, Crimean-Congo hemorrhagic fever, Venezuelan hemorrhagic fever, and Hantavirus infection. Ribavirin is a prodrug that is metabolized into nucleoside analogs that blocks viral RNA synthesis and viral mRNA capping. Before the development of newer drugs, ribavirin and [DB00008]/[DB00022] dual therapy was considered the first-generation and standard antiviral treatment [A19626]. The dual therapy was administered for 48 weeks in patients with genotype 1, 4, 5, and 6, and 24 weeks in patients with genotype 2 and 3 [A19626]. Newer drugs developed as Hepatitis C viral infection treatments can be used to reduce or eliminate the use of ribavirin, which are associated with serious adverse effects. They also improve therapeutic efficacy in patients with failed [DB00008]/[DB00022] and ribavirin-based therapy. The potential use of ribavirin as a treatment for acute myeloid leukemia is currently under investigation. According to 2017 American Association for the Study of Liver Diseases (AASLD) and 2015 consensus guidelines from the Canadian Association for the Study of the Liver (CASL), ribavirin is typically used as an adjunct therapy to various first-line and second-line combination therapies recommended for each genotypes. Ribavirin is added to decrease relapse rates by accelerating viral clearance early in the treatment course [A19645]. When used to treat Hepatitis C virus (HCV) infections, it is always used as a part of combination therapies as ribavirin monotherapy is not efficacious in the treatment of chronic hepatitis C infection [A19644]. Additionally, including ribavirin in the regimen can increase the risk of anemia. In HCV genotye 1/2/3/4/5/6 patients, ribavirin can be used in combination therapy involving [DB09102] and [DB08934], Eplusa ([DB08934], [DB11613]), Harvoni ([DB08934], [DB09027]), [DB06290] and [DB08934], Viekira Pak ([DB09296], [DB09297], [DB00503], [DB09183]), Technivie ([DB00503], [DB09296], [DB09297]) and Zepatier ([DB11574], [DB11575]). Addition of weight-based ribavirin to Technivie therapy increased sustained virologic response after 12 weeks of daily therapy (SVR12) from 90% to 97% in patients with HCV genotype 1a and 90.9% to 100% in HCV genotype 4 patients [L852]. Zepatier therapy along with ribavirin improved SVR in HCV genotype 5 patients. Combination therapy of ribavirin and [DB00008] results in the SVR of 44% in patients with genotype 1 infection and 70% in patients with genotype 2-6. The inclusion of ribavirin in the combination therapies depend on individual patient's profile, for example if HCV genotype 3 patient has a Y93H genetic variant and compensated cirrhosis.
DB00577ValaciclovirValaciclovir (INN) or valacyclovir (USAN) is an antiviral drug used in the management of herpes simplex and herpes zoster (shingles). It is a prodrug, being converted in vivo to [aciclovir]. It is marketed by GlaxoSmithKline under the trade name Valtrex or Zelitrex.
DrugDrug NameTargetType
DB09102DaclatasvirNonstructural Protein 5A (NS5A)target
DB09102DaclatasvirCytochrome P450 3A5enzyme
DB09102DaclatasvirCytochrome P450 3A4enzyme
DB09102DaclatasvirCytochrome P450 3A43enzyme
DB09102DaclatasvirCytochrome P450 3A7enzyme
DB09102DaclatasvirCytochrome P450 3A3enzyme
DB09102DaclatasvirMultidrug resistance protein 1transporter
DB09102DaclatasvirSolute carrier organic anion transporter family member 1B1transporter
DB09102DaclatasvirSolute carrier organic anion transporter family member 1B3transporter
DB09102DaclatasvirATP-binding cassette sub-family G member 2transporter
DB00426FamciclovirDNA polymerase catalytic subunittarget
DB00426FamciclovirDNA polymerase catalytic subunittarget
DB00426FamciclovirAldehyde oxidaseenzyme
DB00426FamciclovirCytochrome P450 3A4enzyme
DB00693FluoresceinIg kappa chain V-II region RPMI 6410target
DB00693FluoresceinDNAtarget
DB00693FluoresceinSolute carrier family 22 member 6transporter
DB00693FluoresceinBile salt export pumptransporter
DB00693FluoresceinMultidrug resistance-associated protein 1transporter
DB00693FluoresceinCytochrome P450 1A1enzyme
DB01141MicafunginArylsulfatase Aenzyme
DB01141MicafunginCatechol O-methyltransferaseenzyme
DB01141Micafungin1,3-beta-glucan synthase component FKS1target
DB00738PentamidineDNAtarget
DB00738PentamidineCytochrome P450 2C19enzyme
DB00738PentamidinetRNA (cytosine(38)-C(5))-methyltransferasetarget
DB00738PentamidineCytochrome P450 2C8enzyme
DB00738PentamidineCytochrome P450 2D6enzyme
DB00738PentamidineCytochrome P450 1A1enzyme
DB00738PentamidineCytochrome P450 3A5enzyme
DB00738PentamidineCytochrome P450 4A11enzyme
DB00635PrednisoneGlucocorticoid receptortarget
DB00635PrednisoneCytochrome P450 3A4enzyme
DB00635PrednisoneMultidrug resistance protein 1transporter
DB00635PrednisoneSolute carrier organic anion transporter family member 1A2transporter
DB00635PrednisoneCytochrome P450 2C19enzyme
DB00635PrednisoneSerum albumincarrier
DB00635PrednisoneCorticosteroid 11-beta-dehydrogenase isozyme 1target
DB00811RibavirinRNA-directed RNA polymerase Ltarget
DB00811RibavirinEctonucleotide pyrophosphatase/phosphodiesterase family member 1target
DB00811RibavirinRNA-directed RNA polymerase catalytic subunittarget
DB00811RibavirinCytosolic purine 5'-nucleotidasetarget
DB00811RibavirinInosine-5'-monophosphate dehydrogenase 1target
DB00811RibavirinGenome polyproteintarget
DB00811RibavirinInosine-5'-monophosphate dehydrogenase 2target
DB00811RibavirinAdenosine kinaseenzyme
DB00811RibavirinEquilibrative nucleoside transporter 1transporter
DB00811RibavirinSolute carrier family 28 member 3transporter
DB00577ValaciclovirThymidine kinasetarget
DB00577ValaciclovirDNA polymerase catalytic subunittarget
DB00577ValaciclovirSolute carrier family 15 member 1transporter
DB00577ValaciclovirSolute carrier family 15 member 2transporter
DB00577ValaciclovirSolute carrier family 22 member 8transporter
DB00577ValaciclovirSolute carrier family 22 member 6transporter
DB00577ValaciclovirSodium- and chloride-dependent neutral and basic amino acid transporter B(0+)transporter
DB00577ValaciclovirIleal sodium/bile acid cotransportertransporter
DrugDrug NamePhaseStatusCount
DB06013Aldoxorubicin2Completed1
DB00704Naltrexone2Completed1
DB02546Vorinostat2Active Not Recruiting1
DB09065Cobicistat4Not Yet Recruiting1
DB01264Darunavir4Not Yet Recruiting1
DB00125L-Arginine4Completed1
DB00709Lamivudine4Completed1
DB01601Lopinavir4Completed1
DB05083Rilpivirine4Not Yet Recruiting1
DB08864Rilpivirine4Not Yet Recruiting1
DB00495Zidovudine4Completed1
DB10300Human papillomavirus type 11 L1 capsid protein antigenNot AvailableCompleted1
DB09153Sodium ChlorideNot AvailableCompleted1